Sarepta Therapeutics Sustainability Profile
Sarepta Therapeutics, Inc., a leading biotechnology company headquartered in the United States, is at the forefront of developing innovative genetic medicine for rare diseases, particularly Duchenne muscular dystrophy (DMD). Founded in 1980, Sarepta has achieved significant milestones, including the development of its pioneering exon-skipping therapies, which offer unique treatment options for patients with DMD. With a strong focus on advancing precision medicine, Sarepta's core products, such as eteplirsen and golodirsen, utilise cutting-edge technology to address the underlying genetic causes of muscular dystrophies. The company has established a prominent market position, recognised for its commitment to transforming the lives of patients through groundbreaking therapies. As it continues to expand its operational reach, Sarepta remains dedicated to innovation and excellence in the biotechnology industry.
DitchCarbon Score
How does Sarepta Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sarepta Therapeutics's score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sarepta Therapeutics's reported carbon emissions
In 2023, Sarepta Therapeutics, headquartered in the US, reported total carbon emissions of approximately 3,428,000 kg CO2e for Scope 1 and about 5,000,000 kg CO2e for Scope 2. This reflects a slight increase in emissions compared to 2022, where Scope 1 emissions were around 2,701,000 kg CO2e and Scope 2 emissions were approximately 4,789,000 kg CO2e. Sarepta has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The absence of reduction targets indicates a potential area for future development in their sustainability strategy. Overall, while Sarepta Therapeutics has made strides in tracking and reporting their emissions, the lack of comprehensive reduction goals suggests that further action may be necessary to align with industry standards for climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,701,000 | 0,000,000 |
| Scope 2 | 4,789,000 | 0,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Sarepta Therapeutics's Industry?
How Carbon Intensive is Sarepta Therapeutics's Location?
Sarepta Therapeutics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sarepta Therapeutics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
